FDA Approves MYCOPHENOLATE MOFETIL — Accord Healthcare Inc.

Accord Healthcare Inc. has announced the addition of Mycophenolate Mofetil—marketed as Myfortic—to its portfolio, providing pharmacists with a B2B500 alternative for immunosuppressive therapy following the FDA's final approval on May 4, 2009. This approved generic intends to impact market pricing structures by offering a cost-effective option to restore patient access for patients managing transplantation and autoimmune conditions.